Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trials

Background: Adenocarcinoma with more than 50% extracellular mucin is a relatively rare histological subtype of gastrointestinal adenocarcinomas. The clinical impact of extracellular mucin in oesophageal adenocarcinoma (OeAC) has not been investigated in detail. We hypothesised that patients with mucinous OeAC (OeACmucin) do not benefit from neoadjuvant chemotherapy. Methods: OeAC patients either treated by surgery alone in the OE02 trial (S-patients) or by neoadjuvant chemotherapy followed by surgery (CS-patients) in OE02 or OE05 trials were included. Cancers from 1055 resection specimens (OE02 [test cohort]: 187 CS, 185 S; OE05 [validation cohort]: 683 CS) were classified as either mucinous (more than 50% of the tumour area consists of extracellular mucin, OeACmucin) or non-mucinous adenocarcinoma (OeACnon-mucin). The relationship between histological phenotype, clinicopathological characteristics, survival and treatment was analysed. Results: Overall, 7.3% and 9.6% OeAC were classified as OeACmucin in OE02 and OE05, respectively. In OE02, the frequency of OeACmucin was similar in S and CS-patients. Patients with OeACmucin treated with surgery alone had a poorer overall survival compared with OeACnon-mucin patients (hazard ratio: 2.222, 95% confidence interval: 1.08–4.56, P = 0.025). Patients with OeACmucin treated with neoadjuvant chemotherapy and surgery had similar survival as OeACnon-mucin patients in test and validation cohort. Conclusions: This is the first study to suggest in a post-hoc analysis of material from two independent phase III clinical trials that the poor survival of patients with mucinous OeAC can be improved by neoadjuvant chemotherapy. Future studies are warranted to identify potential underlying biological, biochemical or pharmacokinetic interactions between extracellular mucin and chemotherapy

Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trials.

BACKGROUND: Adenocarcinoma with more than 50% extracellular mucin is a relatively rare histological subtype of gastrointestinal adenocarcinomas. The clinical impact of extracellular mucin in oesophageal adenocarcinoma (OeAC) has not been investigated in detail. We hypothesised that patients with mucinous OeAC (OeACmucin) do not benefit from neoadjuvant chemotherapy. METHODS: OeAC patients either treated by surgery alone in the OE02 trial (S-patients) or by neoadjuvant chemotherapy followed by surgery (CS-patients) in OE02 or OE05 trials were included. Cancers from 1055 resection specimens (OE02 [test cohort]: 187 CS, 185 S; OE05 [validation cohort]: 683 CS) were classified as either mucinous (more than 50% of the tumour area consists of extracellular mucin, OeACmucin) or non-mucinous adenocarcinoma (OeACnon-mucin). The relationship between histological phenotype, clinicopathological characteristics, survival and treatment was analysed. RESULTS: Overall, 7.3% and 9.6% OeAC were classified as OeACmucin in OE02 and OE05, respectively. In OE02, the frequency of OeACmucin was similar in S and CS-patients. Patients with OeACmucin treated with surgery alone had a poorer overall survival compared with OeACnon-mucin patients (hazard ratio: 2.222, 95% confidence interval: 1.08-4.56, P = 0.025). Patients with OeACmucin treated with neoadjuvant chemotherapy and surgery had similar survival as OeACnon-mucin patients in test and validation cohort. CONCLUSIONS: This is the first study to suggest in a post-hoc analysis of material from two independent phase III clinical trials that the poor survival of patients with mucinous OeAC can be improved by neoadjuvant chemotherapy. Future studies are warranted to identify potential underlying biological, biochemical or pharmacokinetic interactions between extracellular mucin and chemotherapy

Development of an Osmium Redox Polymer Mediated Bioanode and Examination of its Performance in Gluconobacter oxydans Based Microbial Fuel Cell

WOS: 000405309000020Gluconobacter oxydans (G. oxydans) cells together with an osmium redox polymer (ORP) [Osmium (2,2'-bipyridine) 2(poly-vinylimidazole) 10Cl] Cl were combined with a glassy carbon paste electrode (GCPE) to form a bioanode for a microbial fuel cell (MFC) based on G. oxydans. Although there are G. oxydans/ORP combined bioanode in the literature, as far as it is known, this system is the first one where G. oxydans/ORP bioanode is combined with a cathode and a MFC is formed. After the optimization of experimental parameters, analytical characteristics of ORP/G. oxydans/GCPE bioanode were investigated. ORP/G. oxydans/GCPE showed two linear ranges for ethanol substrate as 1.0-30 mM (R-2 = 0.902) and 30-500 mM (R-2 = 0.997) and analytical range as 1.0-1000 mM. Limit of detection (3.0 s/m) and limit of quantification (10 s/m) values were calculated as 1.29 mM and 4.30 mM respectively where the RSD value was 1.16% for n=5. Combining the developed bioanode in the presence of 5.0 mM K3Fe(CN) 6 mediator with a Pt wire cathode a double compartment MFC was obtained via a salt bridge. G. oxydans/GCPE bioanode based MFC had maximum power density of 0.133 mW cm(-2) (at 33.5 mV), maximum current density as 8.73 mA cm(-2) and OCP value of 156 mV. On the other hand, ORP/G. oxydans/GCPE based MFC showed maximum power density as 0.26 mW cm(-2) (at 46.8 mV), maximum current density as 15.079 mA cm(-2) and OCP value of 176 mV

Development of a Bioanode for Microbial Fuel Cells Based on the Combination of a MWCNT-Au-Pt Hybrid Nanomaterial, an Osmium Redox Polymer and Gluconobacter oxydans DSM 2343 Cells

In this work, a carbon felt electrode (CFE) was modified with a multiwalled carbon nanotube-gold-platinum (MWCNT-Au-Pt) hybrid nanomaterial and integrated with an osmium redox polymer (OsRP, [Os(2, 2’-bipyridine)2(poly-vinylimidazole)10Cl]Cl) and Gluconobacter oxydans DSM 2343 (G. oxydans) cells. The developed electrode was used as the bioanode in a 5.0 mM K3Fe(CN)6mediator containing phosphate buffer (pH 6.5) anolyte and combined with a Pt wire cathode in phosphoric acid medium (pH 3.5). As a result, a two chamber microbial fuel cell (MFC) was formed, in which an activated Nafion membrane was used as a proton exchange membrane. The OsRP/G.oxydans/MWCNT-Au-Pt/CFE based bioanode was electrochemically examined in differently deoxygenated bioanode chambers and additionally the amounts of hybrid nanomaterial and OsRP were optimized. In terms of MFC characteristics, it was found that an anaerobic OsRP/G.oxydans/MWCNT-Au-Pt/CFE bioanode based MFC had a maximum power density of 32.1 mW m-2(at 90 mV), a maximum current density of 1032 mA m-2and a charge transfer efficiency (E%) value of 22.30 (open circuit potential 180 mV)